Tumor necrosis factor-α inhibitors are now considered as standard therapy for patients with severe inflammatory bowel disease who do not respond to corticosteroids, but they carry a definite risk of reactivation of tuberculosis. We present a case in which a patient with inflammatory bowel disease developed a de novo tuberculosis infection after the start of anti-tumor necrosis factor-α treatment despite showing negative results in tuberculosis screening. Although there are many case reports of pleural, lymph nodal and disseminated tuberculosis following infliximab therapy, we present the first case report of rectal tuberculosis following infliximab therapy.

Citations

Citations to this article as recorded by  

• Rectal tuberculosis: A systematic review
  Poras Chaudhary, Ashutosh Nagpal, Sam B. Padala, Mangarai Mukund, Lalit K. Bansal, Romesh Lal
  Indian Journal of Tuberculosis.2022; 69(3): 268.     CrossRef
• A case of paradoxical response during anti-tuberculosis treatment in a patient with ulcerative colitis
  Shuhei Hosomi, Naoko Sugita, Atsushi Kanamori, Masaki Ominami, Koji Otani, Noriko Kamata, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Yasuhiro Fujiwara
  Clinical Journal of Gastroenterology.2022; 15(3): 592.     CrossRef
• Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
  Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
  Intestinal Research.2021; 19(4): 419.     CrossRef
• Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population
  Soumajyoti Sarkar, Saumya Panda, Byungsoo Kim, SmritiK Raychaudhuri, Asutosh Ghosh, SibaP Raychaudhuri
  Indian Journal of Dermatology, Venereology and Leprology.2020; 86(1): 1.     CrossRef
• Tuberculosis rectal: presentación clínica infrecuente y diagnóstico diferencial con enfermedad de Crohn
  M. Gompertz, L. Carreño, L.C. Gil La Rotta
  Revista de Gastroenterología de México.2019; 84(4): 524.     CrossRef
• Bacteriologically Determined De Novo Tuberculosis during Tumor Necrosis Factor-α Inhibitor Therapy
  Gen Takahashi, Hiroyuki Kobayashi, Yasuyuki Saito, Sho Ohsawa, Kuniaki Suzuki, Shinichi Ishihara, Takeshi Hisada
  Internal Medicine.2019; 58(24): 3593.     CrossRef
• Rectal tuberculosis: An uncommon clinical presentation and differential diagnosis with Crohn's disease
  M. Gompertz, L. Carreño, L.C. Gil La Rotta
  Revista de Gastroenterología de México (English Edition).2019; 84(4): 524.     CrossRef
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
  Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Intestinal Research.2018; 16(1): 4.     CrossRef
• Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
  Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Journal of Gastroenterology and Hepatology.2018; 33(1): 20.     CrossRef